https://octavianrx.com/news-and-media daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5980abbb-6e72-4f90-bd68-91bd05b89f61/5_News_Science-Footer.png https://octavianrx.com/news-and-media/oct-holdings-announces-rebrand-to-octavian-therapeutics-appointment-of-new-chair-and-fundraising-launch monthly 0.5 2025-02-11 https://octavianrx.com/news-and-media/directorate-appointment-pakne-kc5fn monthly 0.5 2025-01-20 https://octavianrx.com/news-and-media/directorate-appointment-e2scc-9k95z-by2n6 monthly 0.5 2024-11-05 https://octavianrx.com/news-and-media/directorate-appointment-e2scc-9k95z monthly 0.5 2024-09-19 https://octavianrx.com/news-and-media/directorate-appointment-e2scc monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/oct-secures-1205m-to-advance-phase-i-clinical-trial-for-programme-two-l2cgx monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/the-importance-of-patents-wldw9-efhmy monthly 0.5 2024-09-12 https://octavianrx.com/news-and-media/oct-launches-new-website-nens5 monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-executive-interview-azm5f monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/the-importance-of-patents-62lnh monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-plc-3lsm7 monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/phase-i-clinical-trials-results-7yejz monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/how-our-regulatory-approach-differs-from-medical-cannabis-gr847 monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/trigeminal-neuralgia-explained-n4rth monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-plc-nmx2y monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/directorate-appointment-pakne monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/the-importance-of-patents-wldw9 monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/vimeocom/912206668sharecopy-ea92e monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/vimeocom/912206668sharecopy monthly 0.5 2024-08-14 https://octavianrx.com/news-and-media/octs-elevator-pitch-with-doceo monthly 0.5 2024-04-08 https://octavianrx.com/news-and-media/the-importance-of-patents monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/cornerstone-investor-cantheon-is-kudos-for-oct monthly 0.5 2024-04-08 https://octavianrx.com/news-and-media/oct-secures-1205m-to-advance-phase-i-clinical-trial-for-programme-two monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/1537w24e0dw09wj75fszn50y2m5krl monthly 0.5 2024-04-04 https://octavianrx.com/news-and-media/trigeminal-neuralgia-explained monthly 0.5 2024-03-19 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-appoint-dr-tim-corn-cmo-as-exec-director monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-strengthens-board-with-cmo-dr-tim-corn monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/directorate-appointment monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/how-our-regulatory-approach-differs-from-medical-cannabis monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-executive-interview monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-plc monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oct-onboards-new-shareholders-after-phase-i-results monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/phase-i-clinical-trials-results monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/phase-clinical-trial-results monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-ceo-says-objective-absolutely-met-in-lead-asset-trial monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oct-launches-new-website monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/cipn-explained monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oct-emerges-strong-from-a-pivotal-year-nears-release-of-milestone-clinical-trial-results monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/final-does-administered monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-reports-no-adverse-events-in-oct461201-trial monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/oxford-canabinoid-tech-complete-phase-1-clinical-trials-on-programme-1-for-cipn-treatment monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/a-pharmaceutical-approach-to-cannabinoids monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/notice-of-agm monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/2023-final-results monthly 0.5 2024-08-16 https://octavianrx.com/news-and-media/cannabinoids-vs-opioids monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/notice-of-results monthly 0.5 2023-12-16 https://octavianrx.com/news-and-media/research-talks-inclusion monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-officially-on-the-way-after-first-dosing monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-takes-pain-drug-into-phase-i-appoints-leading-pain-expert monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9f454d6c-700d-4c8e-a8cb-5d33855b9f8c/Screenshot+2023-09-25+at+09.56.46.png News & Media - Oxford Cannabinoid Technologies Takes Pain Drug into Phase I; Appoints Leading Pain Expert - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4 monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4-62b2w monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/valentino-parravicini-presents-at-the-association-of-inhalation-toxicologists-annual-conference monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f40f9639-eb42-4d58-a446-9d18d8fe8c9b/Conference+VP+presenting.jpg News & Media - Valentino Parravicini Presents at the Association of Inhalation Toxicologists Annual Conference - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/e5b5aa11-5572-4d8f-9bda-88fb3291d737/Conference+discussion+panel.jpg News & Media - Valentino Parravicini Presents at the Association of Inhalation Toxicologists Annual Conference - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/clinical-biomarkers-cdx-conference-europe-2023 monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/1e4555a4-d508-4cdf-843f-bdb3abbcc24c/Valentino+CB+%26+CDx+Europe.jpg News & Media - Clinical Biomarkers & CDx Conference Europe 2023 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4-62b2w-tr6x6 monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4-62b2w-tr6x6-mb6ns monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/valentino-parravicini-on-careers-in-discovery-podcast monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4-62b2w-tr6x6-mb6ns-sbed8 monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4-62b2w-tr6x6-mb6ns-sbed8-z7xfc monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/investor-meet-company-oct-results-and-company-update monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/research-talks-inclusion-r8d6a-2kpj4-62b2w-tr6x6-l632t monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-ready-to-go-after-phase-1-trial-submission monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-nearly-ready-for-new-phase-1-trial monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-has-good-opportunities-in-both-lead-products-says-analyst monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/outsourcing-in-clinical-trials-uk-ireland-2022-conference-dr-valentino-parravicini monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/ad7eecad-bebb-4560-a21f-5c06d43044a2/Dr.+Valentino+Parravicini+Outsourcing+in+Clinical+Trials+UK+%26+Ireland+conference.jpg News & Media - Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/oct-investor-update-30-may-2022-q-a-questions monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/the-cannabis-conversation-cannabis-vs-opioids-with-valentino-parravicini monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/investor-meet-company-qa-session monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-announces-formation-of-scientific-advisory-board-to-support-clinical-strategy monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/updates-on-lead-programme-1-oct461201-and-programme-2-oct130401-trigeminal-neuralgia-clinical-trial monthly 0.5 2023-09-26 https://octavianrx.com/news-and-media/data-from-pre-clinical-study-show-positive-results monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/requisition-of-general-meeting-update monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-aims-to-get-aggressive-share-of-42-5bln-market-by-2027 monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/requisition-of-general-meeting monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/notice-of-analyst-and-investment-presentation-how-to-register monthly 0.5 2023-09-28 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-drug-development-deal-with-oxford-stemtech monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-in-drug-development-deal-with-oxford-stemtech monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/posting-of-annual-report-notice-of-agm-and-form-of-proxy monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oct-results-and-company-update monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-work-on-treatment-for-chronic-painful-disease-trigeminal-neuralgia monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-targets-chronic-pain-condition-with-latest-formulation monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/pharmafocus monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/good-shape-good-budget-and-on-track-for-oxford-cannabinoid-technologies-holdings monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-deal-for-exclusive-access-to-canopy-growth-s-cannabinoid-library monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-says-admission-to-the-otcqb-is-a-logical-next-step monthly 0.5 2023-11-25 https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-announces-strategic-partnership-with-evotec monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/chief-scientific-officer-valentino-parravicini-to-speak-at-major-cannabinoid-based-drugs-summit-in-boston-massachusetts monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/7542742c-05e3-4782-993d-c146fe8767a8/Valentino+Parravicini.jpg News & Media - Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/meet-the-team-interview-series-dr-john-lucas-chief-executive-officer monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/1a5b9513-45aa-4f95-a6e7-31527678fdf9/Dr+John+Lucas.jpg News & Media - Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-holdings-plc-to-conduct-live-presentations-to-retail-investors- monthly 0.5 2023-09-25 https://octavianrx.com/news-and-media/oct-forges-partnership-with-voisin-consulting-life-sciences- monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/edea4f71-2512-4738-9db4-d77fc3274e89/VCLS+logo.jpg News & Media - OCT Forges Partnership with Voisin Consulting Life Sciences - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://octavianrx.com/news-and-media/oxford-cannabinoid-technologies-announces-changes-to-executive-team monthly 0.5 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/328837a6-9538-4db7-aed0-23ac53447005/Dr+John+Lucas+CEO.jpg News & Media - Oxford Cannabinoid Technologies Announces Changes to Executive Team - Make it stand out Dr John Lucas https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/912285a9-f2e9-47a5-8b23-b52dd21a6609/Clarissa+Sowemimo-Coker.jpg News & Media - Oxford Cannabinoid Technologies Announces Changes to Executive Team - Make it stand out Clarissa Sowemimo-Coker https://octavianrx.com/news-and-media/category/Investor+Meet+Company+Interview monthly 0.5 https://octavianrx.com/news-and-media/category/Annual+Report monthly 0.5 https://octavianrx.com/news-and-media/category/OCT+Partnership monthly 0.5 https://octavianrx.com/news-and-media/category/Program+2+Announcement monthly 0.5 https://octavianrx.com/news-and-media/category/OCT+blog monthly 0.5 https://octavianrx.com/news-and-media/category/iCDP+Speaker monthly 0.5 https://octavianrx.com/news-and-media/category/Article monthly 0.5 https://octavianrx.com/news-and-media/category/OCT+Company+Values monthly 0.5 https://octavianrx.com/news-and-media/category/StemTech monthly 0.5 https://octavianrx.com/news-and-media/category/Conference monthly 0.5 https://octavianrx.com/news-and-media/category/Presentations monthly 0.5 https://octavianrx.com/news-and-media/category/General+Meeting monthly 0.5 https://octavianrx.com/news-and-media/category/Interview monthly 0.5 https://octavianrx.com/news-and-media/category/Investor+Meet monthly 0.5 https://octavianrx.com/news-and-media/category/Live+Presentation monthly 0.5 https://octavianrx.com/news-and-media/category/Procactive+interview monthly 0.5 https://octavianrx.com/news-and-media/category/Programme+Update monthly 0.5 https://octavianrx.com/news-and-media/category/R%26D+Support monthly 0.5 https://octavianrx.com/news-and-media/category/Research+Update monthly 0.5 https://octavianrx.com/news-and-media/category/Developing+Cannabinoids monthly 0.5 https://octavianrx.com/news-and-media/category/Press+release monthly 0.5 https://octavianrx.com/news-and-media/category/Open+Access+Government monthly 0.5 https://octavianrx.com/news-and-media/category/Proactive+Interview monthly 0.5 https://octavianrx.com/news-and-media/category/Scientific+Advisory+Board monthly 0.5 https://octavianrx.com/news-and-media/category/Podcast monthly 0.5 https://octavianrx.com/news-and-media/category/Pharmafocus+Article monthly 0.5 https://octavianrx.com/news-and-media/category/Investor+Questions monthly 0.5 https://octavianrx.com/news-and-media/category/Results+and+Company+Update monthly 0.5 https://octavianrx.com/news-and-media/category/US+Market monthly 0.5 https://octavianrx.com/news-and-media/category/Meet+the+Team+Interview+Series monthly 0.5 https://octavianrx.com/news-and-media/category/Partnership monthly 0.5 https://octavianrx.com/news-and-media/category/Video monthly 0.5 https://octavianrx.com/news-and-media/category/Trigeminal+Neuralgia+Interview monthly 0.5 https://octavianrx.com/news-and-media/category/Canopy+Growth monthly 0.5 https://octavianrx.com/news-and-media/category/Changes+to+Executive+Team monthly 0.5 https://octavianrx.com/news-and-media/tag/Article monthly 0.5 https://octavianrx.com/home daily 1.0 2025-07-18 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b5333e08-0c30-40e6-adc3-93c2005212ee/0_HOME_1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/41384b64-ec18-4e22-b7e3-8fd89f16f139/0_HOME_2.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/a539cb2c-d99e-497f-90a6-d59608d2ada7/0_HOME_3.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/1f092180-0ce1-42d0-b4e1-f42a34110ee8/0_HOME_4.png https://octavianrx.com/our-mission daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f7393e4c-298f-40dc-9d83-5fb08831029c/1_ABOUT_2.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/c568dd95-10d7-4d36-ada2-c3c49cee3f5f/Time-Proven_ICON.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/1a0070d2-89a9-41ea-8291-afbf70e05fcc/Pathway+ICON.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/dc38fe78-8111-4dc3-acb2-c978e38ca483/Quality_ICON.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b0911bf9-2291-49d4-8293-331cfd1397d3/1_ABOUT_3.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/80d69c39-02eb-49d5-bbb2-649ef7748074/1_ABOUT_5.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b95c265e-a11b-4b70-956d-82073bad746e/1_ABOUT_4.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/6a12489d-464d-4d18-83db-57f533f71c07/1_ABOUT_8.png https://octavianrx.com/our-people daily 0.75 2025-02-12 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/46ac5149-3702-4f5c-950e-7541b16c95b9/Darren%2BMott_RL.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/04ee26a8-d1d3-4628-a79d-4a6d0b8b7f8b/Clarissa+Sowemimo-Coker_RR.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/649c2177-dfdc-4bb3-848f-76777c1ccea8/Paul+Smalley_RL.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9bbf20be-b63b-4e25-8c3d-69103c905bf3/Julie_RR.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/441f34d3-ca22-4169-ba36-7f3ce6f77ca6/Dr.+Tim+Corn_RL.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/eaf7b86f-1925-4808-9e41-32a6c505a8da/Neil+Mahapatra_RR.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/e77de6dd-78f0-4a56-b8cb-951445793de1/Dr.+Valentino+Parravicini_RR.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/441f34d3-ca22-4169-ba36-7f3ce6f77ca6/Dr.+Tim+Corn_RL.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f7d4a8fa-81f7-4f05-857b-7e0cd71578ff/Rob+Bennett_RR.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/c634b9be-6cf7-4f17-b261-e7e979c03481/Clarissa+Sowemimo-Coker_RL.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/cb55a528-e609-41ea-b306-0938656550ff/Paul+Smalley_RR.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b7b5f40b-6b72-4a96-b9c8-e54286fda8d6/OCT_WebsiteAssets_300823_Team_Wide.png https://octavianrx.com/our-partners daily 0.75 2023-09-25 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/539b9f5c-8904-4ce1-8247-86f30b735d98/vcls.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/ef9194f4-da68-4476-b4e2-500b5ed61d82/eurofins.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b5161905-63af-4263-843b-0bbc9c3bb71e/apconix.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/28b65dcf-3a43-479c-9f7c-2147ef4f672a/Evotec.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9eef2cfc-9d1e-4bc0-be32-7c950cdb8885/askat+REDRAWN.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5394d532-4f1d-4292-855c-cc8672e1776a/cerebro.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b5161905-63af-4263-843b-0bbc9c3bb71e/apconix.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/539b9f5c-8904-4ce1-8247-86f30b735d98/vcls.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f653dbbe-bee3-4720-9185-506ef8e57393/HT-Presspart.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/466135fa-31e8-40a6-adcd-d8d8e164ea90/charles+river.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5394d532-4f1d-4292-855c-cc8672e1776a/cerebro.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/73fdd1f9-779b-497f-990d-29c8e4cd9562/ozuk.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5d8b16c5-c0e6-48e6-a1cb-610a7724c4ed/Purisys.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b19c721e-ccb4-46b5-af40-49c3c31a0ec1/canopy-growth.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/7ff70971-f6e3-4482-8f4f-dd4344230572/stemtech.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/d1e62ca0-07f9-4683-9786-2e9713b8ba1c/dalriada.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/345bc288-feb7-4fae-a526-8237dcc06de1/1_ABOUT_8.png https://octavianrx.com/visual-pipeline daily 0.75 2024-09-05 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/e22bfb25-0fb9-429c-979d-b7772c848058/Visual+Pipeline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/30b2c832-3327-42b1-93d9-540f3bb38b56/3_PIPELINE_9.png https://octavianrx.com/media-contact daily 0.75 2024-08-14 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9b8e5ca5-9050-4fc3-b1ff-29916a1d1d40/5_NEWS_4.png https://octavianrx.com/press-pack daily 0.75 2023-09-26 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9b8e5ca5-9050-4fc3-b1ff-29916a1d1d40/5_NEWS_4.png https://octavianrx.com/contact daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/dc6ae6b5-3698-456c-89e3-84a804eaad27/2_SCIENCE_14.png https://octavianrx.com/chairs-welcome daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/e2b502cd-6b2d-472c-9bc4-ba9dcae95584/Darren+-+chair.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/business-model-strategy daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/4d3a4e17-1342-4d8e-9d7a-95cb1df28439/4_INVESTORS_6.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/d8eec215-3181-442b-9b22-96b9f0460166/4_INVESTOR_1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/26fbe45e-1423-46b1-855b-5dcb4dd192eb/4_INVESTOR_7.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/annual-report-interim-results daily 0.75 2024-11-28 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/regulatory-news daily 0.75 2025-02-12 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/corporate-governance daily 0.75 2024-08-22 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/fa3802d2-b632-48fd-bc22-d4e3265c3d3b/4_INVESTOR_3.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/07c8a09c-3438-445d-a482-b22713ebb090/4_INVESTOR_2.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/be6a63e3-37aa-491a-ae79-e2e8483b757d/4_INVESTOR_4.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/key-documents daily 0.75 2023-09-26 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/privacy-policy daily 0.75 2025-02-12 https://octavianrx.com/terms-of-use daily 0.75 2025-02-12 https://octavianrx.com/about daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/6d13c1de-ded4-45e9-b8c7-c8f7634322b6/blue1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f01c609f-59d5-47f8-80df-eb4512ed1151/1_ABOUT_Our+Mission.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/af58f0c3-7023-48ea-b727-dedb5b280219/OCT_WebsiteAssets_300823_Team.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/7ff70971-f6e3-4482-8f4f-dd4344230572/stemtech.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/28b65dcf-3a43-479c-9f7c-2147ef4f672a/Evotec.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/73fdd1f9-779b-497f-990d-29c8e4cd9562/ozuk.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/539b9f5c-8904-4ce1-8247-86f30b735d98/vcls.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5394d532-4f1d-4292-855c-cc8672e1776a/cerebro.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/d1e62ca0-07f9-4683-9786-2e9713b8ba1c/dalriada.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9eef2cfc-9d1e-4bc0-be32-7c950cdb8885/askat+REDRAWN.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/ef9194f4-da68-4476-b4e2-500b5ed61d82/eurofins.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b19c721e-ccb4-46b5-af40-49c3c31a0ec1/canopy-growth.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f653dbbe-bee3-4720-9185-506ef8e57393/HT-Presspart.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b5161905-63af-4263-843b-0bbc9c3bb71e/apconix.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5d8b16c5-c0e6-48e6-a1cb-610a7724c4ed/Purisys.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/466135fa-31e8-40a6-adcd-d8d8e164ea90/charles+river.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/1c782e1f-8e8f-4d47-ae4e-35047e507128/1_ABOUT_8.png https://octavianrx.com/science daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b85e7669-9000-4e94-a150-a2048d0732e2/white1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/73a64755-5847-4ba1-ad9a-911433f202aa/2_SCIENCE_13.png https://octavianrx.com/pipeline daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b85e7669-9000-4e94-a150-a2048d0732e2/white1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/30b2c832-3327-42b1-93d9-540f3bb38b56/3_PIPELINE_9.png https://octavianrx.com/investors daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b85e7669-9000-4e94-a150-a2048d0732e2/white1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/e2b502cd-6b2d-472c-9bc4-ba9dcae95584/Darren+-+chair.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5e9bfe8a-c52c-4a2f-a0cb-13b93f363801/4_INVESTORS_17.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/fa0304c3-5b79-4a82-a68d-0abf7d5db5fd/4_Investment_Board+of+Directors.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/10339b28-2873-43e1-a519-86a35c24005b/4_INVESTORS_16.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/404ca65e-8bc9-40fe-b211-f417228dbf48/WebsiteAssets_050923_5.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b17fcdcf-8801-43d4-9a11-2b3053bd0cde/4_Investor_ICON-Q%2BA.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/71a8af9e-337e-4eab-9be2-fd74d08cdefc/4_Investor_ICON-Research-Reports.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/f1a04b7a-96f4-4ac2-b6ba-5dcc94452cb8/WebsiteAssets_050923_4.png https://octavianrx.com/news daily 0.75 2025-02-11 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/b85e7669-9000-4e94-a150-a2048d0732e2/white1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/e7011a2e-b83a-4699-8882-1838388a1f8d/5_NEWS_3.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/634727bd-30cd-4986-9a2c-7d954aad64f7/5_NEWS_1.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/110f40d2-a9b1-4321-bde9-af700bda7b29/5_News_OCT+yellow+keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/9b8e5ca5-9050-4fc3-b1ff-29916a1d1d40/5_NEWS_4.png https://octavianrx.com/research-reports daily 0.75 2023-09-26 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png https://octavianrx.com/investor-qa daily 0.75 2025-02-12 https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/5c533998-3cc0-4622-8137-0654072f00a0/4_Investor_OCT-Keyline.png https://images.squarespace-cdn.com/content/v1/64e5d3a8d95a703abae4b111/877132ee-ba95-4c47-a4e8-04818bbcf254/4_INVESTOR_5.png